Jeffrey Robert Ajer

CIK: 0001557533

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

NKTR

NEKTAR THERAPEUTICS

Director

$Viridian Therapeutics, Inc.\DE logo$

VRDN

Viridian Therapeutics, Inc.\DE

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

NKTR
NEKTAR THERAPEUTICS
Sep 23, 2026
Award(A)
Direct
2K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Jul 1, 2026
Award(A)
Stock Option (Right to Buy)
Direct
32.3K shares-
NKTR
NEKTAR THERAPEUTICS
Sep 30, 2025
Award(A)
Stock Option
Direct
8K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Jul 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
21K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Apr 7, 2025
Award(A)
Stock Option (Right to Buy)
Direct
42K shares-
NKTR
NEKTAR THERAPEUTICS
Sep 18, 2024
Award(A)
Stock Option
Direct
120K shares-

		Type	Shares	Price		Ownership
Sep 23, 2026	NKTR NEKTAR THERAPEUTICS	Award(A)	2,000	-	$0	Direct
Jul 1, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Stock Option (Right to Buy)	32,341	-	-	Direct
Sep 30, 2025	NKTR NEKTAR THERAPEUTICS	Award(A) Stock Option	8,000	-	-	Direct
Jul 1, 2025	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Stock Option (Right to Buy)	21,000	-	-	Direct
Apr 7, 2025	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Stock Option (Right to Buy)	42,000	-	-	Direct
Sep 18, 2024	NKTR NEKTAR THERAPEUTICS	Award(A) Stock Option	120,000	-	-	Direct

1-6 of 6 transactions

About Ajer Jeffrey Robert

Ajer Jeffrey Robert (SEC CIK 0001557533) files insider reports with the SEC as Director of NEKTAR THERAPEUTICS (NKTR) and Director of Viridian Therapeutics, Inc.\DE (VRDN).

Signal8 holds 7 ownership filings by Ajer Jeffrey Robert (1 Form 3, 5 Form 4, 1 Form 5), filed between Jan 17, 2025 and Sep 25, 2026. Those filings report 6 transactions, from Sep 18, 2024 to Sep 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ajer Jeffrey Robert's filings is in SAN FRANCISCO, CA.

Recent filings by Ajer Jeffrey Robert

Sep 23, 2026: Grant or award of NKTR shares (Form 4, code A).
Jul 1, 2026: Grant or award of VRDN derivative securities (Form 4, code A).
Sep 30, 2025: Grant or award of NKTR derivative securities (Form 4, code A).
Jul 1, 2025: Grant or award of VRDN derivative securities (Form 4, code A).
Apr 7, 2025: Grant or award of VRDN derivative securities (Form 4, code A).

Other insiders filing for NEKTAR THERAPEUTICS (NKTR)

WHITFIELD ROY A, Director
GREER R SCOTT, Director
CHESS ROBERT, Director
Brainard Diana, Director
Zalevsky Jonathan, Chief R&D Officer
ROBIN HOWARD W, President & CEO

How to read Form 4 transaction codes